Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-209 pemigatinib in previously treated FGFR-altered primary CNS tumors
2021-004740-24Phase 2Completed
- Sponsor
- Incyte
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemigatinib in glioblastoma (GBM), glioma, astrocytoma and 1 more (2 cohorts), sponsored by Incyte. Primary endpoint: Objective response rate in Cohort A. Started Feb 2022; status: completed.
02
Drugs
pemigatinib
03
Conditions
glioblastoma (GBM)gliomaastrocytomacentral nervous system primary tumor
Beyond the preview
Go deeper on 2021-004740-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004740-24.